CloudMD Software & Services Inc., - CEO, Dr Essam Hamza.
CEO, Dr Essam Hamza.
Source: The Vancouver Sun.
  • CloudMD (DOC) has closed an C$8.2 million over-allotment option
  • The company sold 3,060,000 common shares at C$2.70 per share for gross proceeds of C$8,262,000
  • The shares were issued to exercise an over-allotment option granted to Canaccord Genuity et al. on behalf of a syndicate of underwriters
  • CloudMD offers SAAS-based technology solutions to healthcare providers across North America
  • CloudMD (DOC) is down 1.79 per cent and is currently trading at C$2.20 per share

CloudMD (DOC) has closed an C$8.2 million over-allotment option.

The company sold 3,060,000 common shares at C$2.70 per share for gross proceeds of C$8,262,000.

The shares were issued to exercise an over-allotment option granted to Canaccord Genuity, Beacon Securities Limited and Echelon Wealth Partners on behalf of a syndicate of underwriters including Laurentian Bank Securities and Mackie Research Capital Corporation.

The company issued the underwriters an additional 214,200 broker warrants in connection with its bought deal short form prospectus offering.
Each broker warrant is exercisable to acquire one common CloudMD share at C$2.70 for a period of 24 months following the closing date of the offering.

CloudMD offers SAAS-based technology solutions to healthcare providers across North America. CloudMD (DOC) is down 1.79 per cent and is currently trading at C$2.20 per share as of 10:59 am EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.